Azienda Ospedaliera S Giovanni Addolorata — Clinical Trial Site

38 Registered trials

19 Currently recruiting

Organisation

Azienda Ospedaliera S Giovanni Addolorata

Location

Rome, Italy

Identifier

ORG-100030771

Address

Via Merulana 143, 00185, Italy

Departments

Cardio Thoracic Vascular Department
DIPARTIMENTO SPECIALITÀ
DIPARTIMENTO SPECIALITÀ - UOC EMATOLOGIA
N/A
Oncologia
Oncologia Medica
Oncology
Reparto di Oncologia Medica
S.C. Ematologia - AO San Giovanni Addolorata
Sensory Organs
U.O.C. Oncologia
Unità Clinica di Fase I di Oncologia, Ematologia, Medicina Nucleare
Unità Operativa Complessa Oncologia
UOC CARDIOLOGIA D'URGENZA E UTIC
UOC Ematologia
UOC Gastroenterologia Endoscopia Digestiva
UOC Oncologia
UOC Oncology
UON Oncologia
UON Oncology
UOSD Terapia Antalgica

Clinical trials at this site (38)

Search interface

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Small cell lung cancer (SCLC) 5 2023-12-18
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 5 2023-02-09
Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2) Ended

2024-517424-18-00 Patients with EGFR mutant NSCLC according to TP53 muta 6 2022-05-10
Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients sufferi… Ended

2023-510432-36-00 Acute Myeloid Leukemia with NPM1 mutation 4 2022-03-01
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended

2023-508968-30-00 Adult Philadelphia Chromosome-Positive Acute Lymphoblas 5 2021-09-08
Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cel… Ended

2024-511637-35-00 Elderly patients with Diffuse Large B-Cell Lymphoma (DL 5 2021-03-23
SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of… Ended

2022-502697-16-00 Neurotrophic Keratopathy 5 2023-08-29
Sotorasib and Panitumumab Versus Investigator’s Choice for Subjects with KRAS p.G12C Mutation (CodeBreaK 300) Ended

2024-511187-81-00 Colorectal Cancer (CRC) 5 2022-03-28
Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J… Ended

2023-505457-40-00 Previously Untreated Advanced Gastric or Gastroesophage 5 2022-02-02
A phase 2, multicenter, randomized, double blind, active controlled, parallel group study assessing the analgesic effect and safety of two d… Ended

2024-513940-27-00 Chronic low back pain 4 2021-11-19
MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non… Ended

2022-501252-28-00 Non Small Cell Lung cancer 4 2021-04-15
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended

2023-505035-12-00 RET fusion−positive, metastatic Non-Small Cell Lung Can 5 2020-06-12
Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended

2022-500413-11-00 Unresected Stage I or II Non-Small Cell Lung Cancer (NS 5 2019-06-17
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended

2024-514515-10-00 Breast Cancer 5 2016-06-16